E6201
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for E6201, covering 2017-02-06 to 2025-08-19. Get the full timeline:
Most recent: Clinical Trial Update: E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma [Phase 1]